Doral (Quazepam) Shortage: What Providers and Prescribers Need to Know in 2026

Prescribers who have patients on Doral (quazepam) are increasingly encountering a frustrating situation: patients call to report they cannot get their prescription filled, even though the drug is not on any official shortage list. This article is a comprehensive briefing for providers on the current quazepam access landscape in 2026, including actionable steps to help your patients.

Clinical Overview: Quazepam's Place in Sleep Medicine

Quazepam (Doral) was FDA-approved in 1985 for insomnia characterized by difficulty falling asleep, frequent nocturnal awakenings, and early morning awakenings. It is a 1,4-benzodiazepine with relatively selective binding to type 1 benzodiazepine (omega-1) receptors, which distinguishes it pharmacologically from other benzodiazepines that bind non-selectively.

Quazepam's notably long half-life (approximately 40 hours for the parent compound, with active metabolites including N-desalkylflurazepam persisting 36-120 hours) provides durable sleep induction and maintenance effects. Research has shown minimal rebound insomnia upon discontinuation compared to shorter-acting benzodiazepines. For some patients — particularly those with chronic insomnia who have failed shorter-acting agents — quazepam provides clinical benefits that are difficult to replicate with alternatives.

The Supply Situation in 2026: Not a Shortage, But Still a Problem

As of 2026, quazepam is not listed on the FDA Drug Shortage Database or the ASHP shortage list. However, several compounding factors have made it effectively inaccessible through standard retail pharmacy channels:

• Brand Doral discontinued. The original brand-name product has been discontinued by GALT Pharms as of late 2025. Only authorized generic quazepam 15 mg remains.
• Limited distributor coverage. The authorized generic is not broadly distributed through the major pharmaceutical wholesalers (McKesson, AmerisourceBergen, Cardinal Health) that supply chain pharmacies. Most major chains (CVS, Walgreens, Rite Aid, Walmart) cannot obtain it.
• Extremely low prescription volume. Quazepam represents a small fraction of all sleep prescription fills. Pharmacies routinely decline to stock Schedule IV drugs they rarely dispense due to DEA compliance burden.

Controlled Substance Prescribing Considerations

Quazepam is classified as a Schedule IV controlled substance. Key prescribing considerations that differ from non-controlled sleep aids include:

• Refill limitations. Schedule IV prescriptions are limited to 5 refills within 6 months of the original prescription date. After that, a new prescription is required.
• Telehealth prescribing rules. The DEA has issued rules extending flexibility for prescribing Schedule IV substances via telemedicine under certain conditions. As of 2026, DEA-registered providers with a bona fide prescriber-patient relationship can prescribe Schedule IV medications via telemedicine in many circumstances.
• Boxed warning documentation. All benzodiazepines carry FDA boxed warnings for abuse, misuse, addiction, physical dependence, and withdrawal reactions. Patient counseling documentation is essential.

The Boxed Warning: What Providers Must Communicate

The quazepam labeling carries a boxed warning covering three major risk areas that must be communicated to patients:

1. Risks from concomitant use with opioids: Profound sedation, respiratory depression, coma, and death. Reserve concomitant use for patients without adequate alternatives and use minimum doses and durations.
2. Abuse, misuse, and addiction: Patients with history of substance use disorders require careful surveillance. Quazepam's long half-life may provide a buffer against some abuse patterns but does not eliminate risk.
3. Dependence and withdrawal reactions: Abrupt discontinuation can precipitate acute withdrawal, including seizures. A gradual taper is required after extended use.

How to Help Patients Access Quazepam in 2026

If your patient needs quazepam, here are the most reliable options:

1. E-prescribe or fax to Sterling Specialty Pharmacy (e-scribe #2433693, fax: 866-588-0371, phone: 888-618-4126). This specialty pharmacy in Mendota Heights, MN is the primary supplier listed on doralrx.com and ships nationwide.
2. Direct patients to independent pharmacies with the specific ask to source quazepam 15 mg from their wholesaler. This can take 2-5 business days but may work locally.
3. Refer patients to medfinder for providers — a service that calls pharmacies near patients to check which ones can fill their specific prescription. This saves patients significant time and reduces the chance of missed doses during transitions.

Clinical Alternatives If Quazepam Cannot Be Sourced

If quazepam truly cannot be sourced for your patient, the following alternatives are widely available and share some pharmacological overlap:

• Temazepam (Restoril) 15-30 mg: Closest benzodiazepine alternative; treats sleep onset and maintenance; shorter half-life reduces accumulation risk
• Eszopiclone (Lunesta) 1-3 mg: Z-drug with FDA approval for both onset and maintenance; widely available as generic
• Suvorexant (Belsomra) 10-20 mg: Orexin receptor antagonist; good for maintenance; lower dependence risk profile
• Doxepin (Silenor) 3-6 mg: FDA-approved for sleep maintenance; low-dose tricyclic; not a controlled substance; good for elderly patients

Key Takeaways for Prescribers

• Quazepam is not in formal shortage but is de facto unavailable at most retail pharmacies
• Always e-prescribe or fax directly to Sterling Specialty Pharmacy for reliable fulfillment
• Counsel patients on the boxed warning before prescribing and document accordingly
• Have a taper plan ready in case the medication becomes permanently unavailable for a patient